Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating Efficacy and Safety of Inupadenant in Combination With Carboplatin and Pemetrexed in Adults With Nonsquamous Non-small Cell Lung Cancer Who Have Progressed on Immunotherapy

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating Efficacy and Safety of Inupadenant in Combination With Carboplatin and Pemetrexed in Adults With Nonsquamous Non-small Cell Lung Cancer Who Have Progressed on Immunotherapy

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Inupadenant (Primary) ; Carboplatin; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors iTeos Therapeutics

Most Recent Events

  • 12 Dec 2024 According to an iTeos Therapeutics media release, interim data from this trial presented at the European Society for Medical Oncology Immuno-Oncology (ESMO IO) Congress 2024.
  • 12 Dec 2024 Interim data from the dose escalation portion of A2A-005 trial presented in the iTeos Therapeutics Media Release
  • 24 Oct 2024 According to an iTeos Therapeutics media release, the clinical and translational data from the dose escalation portion of this trial assessing inupadenant and platinum-doublet chemotherapy in metastatic non-small cell lung cancer (NSCLC) patients, will be presented as 2 different mini oral presentations on December 12, 2024 at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2024, being held December 11-13, 2024 in Geneva, Switzerland.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top